Another Patent-Infringement Setback for Myriad Genetics

William Gaede said that he and client Ambry Genetics “are pleased” that a Utah federal court refused to block a bid by Myriad Genetics to halt Ambry’s sale of a competing cancer test. Mr. Gaede noted that “the court found we made a clear and convincing showing that the Myriad’s claims encompassed unpatentable subject matter,” and added, “The court’s ruling is consistent with the Supreme Court’s AMP and Mayo decisions.”